Navigation Links
Amarantus BioScience to Present at the 15th Annual BIO CEO & Investor Conference
Date:2/8/2013

SUNNYVALE, Calif., Feb. 8, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Gerald E. Commissiong , President and Chief Executive Officer will present a corporate update  at the 15th Annual BIO CEO & Investor Conference hosted by the Biotechnology Industry Organization (BIO). The presentation will take place on Monday, February 11, 2013 at the Waldorf Astoria in New York, NY.

The presentation will be webcast and available in the IR Calendar section of the Company's website at www.amarantus.com

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.

CORPORATE CONTACTS

Amarantus Bioscience, Inc. 
ir@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
(408) 737-2734 x109
remy@irsense.com


'/>"/>
SOURCE Amarantus BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... Business Officer, will present at the 5th Annual ... provide a platform to present to and meet ... pharmaceutical and biotech companies as well as institutional ...
(Date:3/20/2017)... ... March 20, 2017 , ... HOLLOWAY AMERICA, ... recently announced it will debut a brand new pressure vessel, the intelliVessel™, at ... controlled by a touch screen panel and features other revolutionary operations that promote ...
(Date:3/20/2017)... , ... March 20, 2017 , ... The fourth annual ... while innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... challenge every 5 weeks and awards thousands in cash prizes to engineers, inventors and ...
(Date:3/20/2017)... , March 20, 2017  Attorney Advertising -- Bronstein, Gewirtz ... purchasers of the BioAmber Inc. ("BioAmber" or the "Company") (NYSE: ... information and assist the investigation by visiting the firm,s site: ... BioAmber and certain of its officers and/or directors have violated ... 1934. ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
Breaking Biology News(10 mins):